Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Roberts

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Biologics : Targets & Therapy|May 15, 2013
Clinical use of crizotinib for the treatment of non-small cell lung cancerPatrick J Roberts
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
KRAS mutation: should we test for it, and does it matter?Patrick J Roberts, Thomas E Stinchcombe
Methods in Molecular Biology (Clifton, N.J.)|December 7, 2011
Posttranslational lipid modification of Rho family small GTPasesNatalia Mitin, Patrick J Roberts, Emily J Chenette, et al.
Molecular Cancer Therapeutics|June 18, 2020
Chemotherapy and CDK4/6 Inhibitors: Unexpected BedfellowsPatrick J Roberts, Vishnu Kumarasamy, Agnieszka K Witkiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Patrick J Roberts, Thomas E Stinchcombe, Channing J Der, et al.
Molecular Cancer Therapeutics|January 31, 2016
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced MyelosuppressionJohn E Bisi, Jessica A Sorrentino, Patrick J Roberts, et al.
Oncotarget|April 19, 2017
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumorsJohn E Bisi, Jessica A Sorrentino, Jamie L Jordan, et al.
The Journal of Biological Chemistry|July 11, 2008
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modificationPatrick J Roberts, Natalia Mitin, Patricia J Keller, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biologics : Targets & Therapy|May 15, 2013
Clinical use of crizotinib for the treatment of non-small cell lung cancerPatrick J Roberts
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
KRAS mutation: should we test for it, and does it matter?Patrick J Roberts, Thomas E Stinchcombe
Methods in Molecular Biology (Clifton, N.J.)|December 7, 2011
Posttranslational lipid modification of Rho family small GTPasesNatalia Mitin, Patrick J Roberts, Emily J Chenette, et al.
Molecular Cancer Therapeutics|June 18, 2020
Chemotherapy and CDK4/6 Inhibitors: Unexpected BedfellowsPatrick J Roberts, Vishnu Kumarasamy, Agnieszka K Witkiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Patrick J Roberts, Thomas E Stinchcombe, Channing J Der, et al.
Molecular Cancer Therapeutics|January 31, 2016
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced MyelosuppressionJohn E Bisi, Jessica A Sorrentino, Patrick J Roberts, et al.
Oncotarget|April 19, 2017
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumorsJohn E Bisi, Jessica A Sorrentino, Jamie L Jordan, et al.
The Journal of Biological Chemistry|July 11, 2008
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modificationPatrick J Roberts, Natalia Mitin, Patricia J Keller, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Pageof 2